Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Kalaris Therapeutics Inc (NASDAQ: KLRS) closed at $8.44 up 0.72% from its previous closing price of $8.38. In other words, the price has increased by $0.72 from its previous closing price. On the day, 0.12 million shares were traded. KLRS stock price reached its highest trading level at $8.885 during the session, while it also had its lowest trading level at $8.31.
Ratios:
For a deeper understanding of Kalaris Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.89 and its Current Ratio is at 12.89. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
. In the most recent recommendation for this company, Chardan Capital Markets on December 23, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On November 03, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $20.
On September 03, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $23.Raymond James initiated its Strong Buy rating on September 03, 2025, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 26 ’25 when Hagen Brett R sold 907 shares for $8.97 per share. The transaction valued at 8,135 led to the insider holds 1,925 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KLRS now has a Market Capitalization of 157848400 and an Enterprise Value of 82394408.
Stock Price History:
The Beta on a monthly basis for KLRS is -0.07, which has changed by -0.19033813 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, KLRS has reached a high of $12.90, while it has fallen to a 52-week low of $2.14. The 50-Day Moving Average of the stock is 28.32%, while the 200-Day Moving Average is calculated to be 69.06%.
Shares Statistics:
For the past three months, KLRS has traded an average of 173.61K shares per day and 223090 over the past ten days. A total of 18.70M shares are outstanding, with a floating share count of 3.54M. Insiders hold about 81.09% of the company’s shares, while institutions hold 7.83% stake in the company. Shares short for KLRS as of 1765756800 were 503479 with a Short Ratio of 2.90, compared to 1763078400 on 428091. Therefore, it implies a Short% of Shares Outstanding of 503479 and a Short% of Float of 10.6400006.
Earnings Estimates
The stock of Kalaris Therapeutics Inc (KLRS) is currently in the spotlight, with 6 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.52 and low estimates of -$0.73. Analysts are recommending an EPS of between -$2.8 and -$4.49 for the fiscal current year, implying an average EPS of -$3.7. EPS for the following year is -$2.48, with 6.0 analysts recommending between -$2.1 and -$2.89.
